-+ 0.00%
-+ 0.00%
-+ 0.00%

TIVDAK® (TISOTUMAB VEDOTIN) APPROVED BY EUROPEAN COMMISSION FOR PREVIOUSLY TREATED RECURRENT OR METASTATIC CERVICAL CANCER

Reuters·03/31/2025 15:20:00

Please log in to view news